Employer-mandated enrollment in a high-deductible health plan did not reduce use of oral targeted anticancer medications among patients commercially insured between 2007 and 2021.
|Articles|December 1, 1998
Supplements and Featured Publications
- New Developments in the Treatment of Hypertension: What the HOT Study Means to JNC-VI
- Volume 4
- Issue 13 Suppl
Hypertension in the Older Patient
Author(s)Gary Gerstenblith, MD
Advertisement
Articles in this issue
almost 28 years ago
Participating Facultyalmost 28 years ago
Introductionalmost 28 years ago
Barriers to Guideline Adherencealmost 28 years ago
Hypertension in Managed Carealmost 28 years ago
Beta Blockers as First-Line Therapy for Hypertension in the Elderlyalmost 28 years ago
Cost Effectiveness of Intensive Treatment of Hypertensionalmost 28 years ago
Selected Abstractsalmost 28 years ago
CME Quizalmost 28 years ago
BibliographyAdvertisement
Related to this article
We identify the health system characteristics associated with greater or lesser documentation of patients’ social determinants of health.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
4
Who Recommends COVID-19 Vaccines Without ACIP?
5